Strengthening the Reporting of Pharmacogenetic Studies (STROPS) guideline.

VernacularTitle:加强药物基因组学研究报告规范（STROPS）及解读
Author: Xin Ran LU ¹ ; Xue Feng LAI ¹ ; Feng SUN ¹ ; Si Yan ZHAN ² ; Sheng Feng WANG ¹
Author Information

1. Department of Epidemiology and Biostatistics School of Public Health, Peking University, Beijing 100191, China.
2. Department of Epidemiology and Biostatistics School of Public Health, Peking University, Beijing 100191, China Center for Clinical Epidemiology, Peking University Third Hospital, Beijing 100191, China.
Publication Type:Meta-Analysis
MeSH: Genetic Association Studies; Humans; Pharmacogenomic Testing; Research Report
From: Chinese Journal of Epidemiology 2022;43(5):747-754
CountryChina
Language:Chinese
Abstract: Pharmacogenetic studies are designed to investigate the associations between genetic variation and treatment response for a particular drug in terms of both efficacy and adverse events and have high sample size requirements. To improve the quality of pharmacogenetic studies and facilitate the Meta-analyses to investigate statistically significant associations, Strengthening the Reporting of Pharmacogenetic Studies (STROPS) guideline was developed in 2020 based on the Strengthening the Reporting of Genetic Association Studies (STREGA) statement. The objective of this article is to present a brief introduction to the STROPS guideline and an interpretation of the key points in some items with examples for the better understanding and application.